Multistakeholder meetings held as part of US Food and Drug Administration (FDA) patient-focused drug development efforts have left a huge impact on everyone involved, according to Theresa Mullin, PhD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results